Drug research giant AbbVie announced a offer to buy most cancers drug startup Stemcentrx in a $5.eight billion hard cash and stock offer this early morning. The phrases of the offer consist of $2 billion in hard cash and $3.eight billion in stock upfront, additionally a further $4 billion in milestone-dependent payouts to StemCentrx, and $3.eight in stock. The offer values the company at up to $10.2 billion, according to a memo from early StemCentrx trader Founders Fund. The VC business promises Stemcentrx as its most significant financial commitment to day at $300 million. This is the 3rd acquisition for AbbVie so much as it can make moves into most cancers drug research. The drug company ordered Pharmacyclics past yr for $21 billion for a promising most cancers drug. Stemcentrx at present has five most cancers drug trials in the pipeline, with a target on attacking the stem cells dependable for making tumors. “We believe the acquisition of Stemcentrx will strengthen and accelerate our ability to provide progressive therapies that will have a amazing affect on patients’ lives,” Abbvie CEO Richard A. Gonzalez claimed in a statement. The offer is also a nod to Founders Fund wager in biotech. The business likes to invest in reducing-edge technological innovation but is not commonly viewed as a med-tech financial commitment business. Even so, the news would make Stemcentrx the most significant portfolio exit in the historical past of Founders Fund. The offer is envisioned to close in Q2 of 2016.
Source hyperlink Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on Google+ (Opens in new window)
Related
Drug research giant AbbVie announced a offer to buy most cancers drug startup Stemcentrx in a $5.eight billion hard cash and stock offer this early morning. The phrases of the offer consist of $2 billion in hard cash and $3.eight billion in stock upfront, additionally a further $4 billion in milestone-dependent payouts to StemCentrx, and $3.eight in stock. The offer values the company at up to $10.2 billion, according to a memo from early StemCentrx trader Founders Fund. The VC business promises Stemcentrx as its most significant financial commitment to day at $300 million. This is the 3rd acquisition for AbbVie so much as it can make moves into most cancers drug research. The drug company ordered Pharmacyclics past yr for $21 billion for a promising most cancers drug. Stemcentrx at present has five most cancers drug trials in the pipeline, with a target on attacking the stem cells dependable for making tumors. “We believe the acquisition of Stemcentrx will strengthen and accelerate our ability to provide progressive therapies that will have a amazing affect on patients’ lives,” Abbvie CEO Richard A. Gonzalez claimed in a statement. The offer is also a nod to Founders Fund wager in biotech. The business likes to invest in reducing-edge technological innovation but is not commonly viewed as a med-tech financial commitment business. Even so, the news would make Stemcentrx the most significant portfolio exit in the historical past of Founders Fund. The offer is envisioned to close in Q2 of 2016.
Drug research giant AbbVie announced a offer to buy most cancers drug startup Stemcentrx in a $5.eight billion hard cash and stock offer this early morning.
The phrases of the offer consist of $2 billion in hard cash and $3.eight billion in stock upfront, additionally a further $4 billion in milestone-dependent payouts to StemCentrx, and $3.eight in stock.
The offer values the company at up to $10.2 billion, according to a memo from early StemCentrx trader Founders Fund.
The VC business promises Stemcentrx as its most significant financial commitment to day at $300 million.
This is the 3rd acquisition for AbbVie so much as it can make moves into most cancers drug research. The drug company ordered Pharmacyclics past yr for $21 billion for a promising most cancers drug.
Stemcentrx at present has five most cancers drug trials in the pipeline, with a target on attacking the stem cells dependable for making tumors.
“We believe the acquisition of Stemcentrx will strengthen and accelerate our ability to provide progressive therapies that will have a amazing affect on patients’ lives,” Abbvie CEO Richard A. Gonzalez claimed in a statement.
The offer is also a nod to Founders Fund wager in biotech. The business likes to invest in reducing-edge technological innovation but is not commonly viewed as a med-tech financial commitment business. Even so, the news would make Stemcentrx the most significant portfolio exit in the historical past of Founders Fund.
The offer is envisioned to close in Q2 of 2016.